Track RenovoRx Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

RenovoRx Inc. Common Stock RNXT · Stock Open RenovoRx Inc. Common Stock in new tab

1.04 USD
EPS
-0.31
P/B
7.84
ROE
-125.23
Beta
1.17
Target Price
7.25 USD
Loading chart...
Key Metrics
Earnings dateMarch 29, 2027
EPS-0.31
Book Value0.15
Price to Book7.84
Debt/Equity4.34
% Insiders3.595%
Growth
Revenue Growth1.15%
Estimates
Forward P/E-9.67
Forward EPS-0.12
Target Mean Price7.25

DCF valuation

Model fair value for RenovoRx Inc. Common Stock (RNXT)
Result
Sign in to run the valuation for RNXT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Strong buy · mean target 7.25 USD (low 3.00, high 15.00) · as of 12 Nov 2026
Low 3.00
Mean 7.25
High 15.00
Price 1.04
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

RenovoRx Inc. Common Stock Logo RenovoRx Inc. Common Stock Analysis (RNXT)

United States Health Care Official Website Stock

Is RenovoRx Inc. Common Stock a good investment? RenovoRx Inc. Common Stock (RNXT) is currently trading at 1.04 USD. Market analysts have a consensus price target of 7.25 USD. This suggests a potential upside from current levels.

Earnings Schedule: RenovoRx Inc. Common Stock is expected to release its next earnings report on March 29, 2027. The market consensus estimate for Forward EPS is -0.12.

Investor FAQ

Does RenovoRx Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is RenovoRx Inc. Common Stock?

RenovoRx Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 29, 2027. The company currently has a trailing EPS of -0.31.

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Exchange Ticker
NMS (United States) RNXT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion